Future Market Insights (FMI), a leading market research firm, has released its latest industry analysis, revealing that the global yeast infection treatment market demand is poised to reach US$ 6479.8 million by 2024. The market is expected to witness a robust Compound Annual Growth Rate (CAGR) of 5.0%, projecting an estimated market size of US$ 10031.3 million by 2034.

The surge in demand for yeast infection treatment is primarily attributed to the increasing prevalence of yeast and fungal infections, notably affecting areas such as skin, hair, nails, and lungs. Future Market Insights identifies this rising demand as a key driver propelling the expansion of the global yeast infection treatment market.

Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18675

Furthermore, the market is experiencing growth impetus from the escalating rates of illnesses such as Candidiasis and Mucormycosis. These health concerns have underscored the necessity for effective treatment solutions, contributing to the overall upward trajectory of the market. 

The broad availability of drugs for treating yeast and fungal infections and a variety of over-the-counter medications for dermal infections are the key drivers propelling the market. Players are encouraged to spend on research and development, which drives the growth of effective medications for improved results. 

Leading firms pursue several strategic activities to increase their market share, including mergers and acquisitions, regional growth, and investments. Furthermore, businesses are concentrating on getting permits for innovative items that can fill gaps in the market. 

Key Takeaways from the Market Study:

• Azoles have led in terms of treatment type and held around 52.3% market share in 2022.
• Based on indication, genital candidiasis is the leading segment, holding around 63.4% of the market share in 2022.
• North America is expected to surge at a CAGR of 5.2% throughout the forecast period.
• The global market is projected to reach a valuation of US$ 10031.3 million in 2034.
• The yeast infection treatment market is expected to surge at a CAGR of 5.0% by 2034.

"It is projected that the yeast infection treatment market will expand due to rising rates of vaginal yeast infections worldwide. Leading players are focusing on new product launches and government approvals to expand their market presence," opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Key Companies Profiled:

• Astellas Pharma Inc.
• Astra Zeneca
• Abbott Laboratories
• Allergan
• Brundavan Laboratories Private Limited
• Bayer
• Corden Pharma
• Merck & Co., Inc.
• Novartis
• Pfizer Inc.
• Synmedic Laboratories
• Sanofi

Competitive Landscape:

Several local, new, and existing players are present in the yeast infection treatment market. Key players have started marketing campaigns to sell new drugs and topical treatments that will treat yeast infections more effectively and with fewer adverse effects.

For instance,

• In October 2022, Intas launched Itraconazole-SB, a novel antifungal medication. This new medication will drastically save costs and improve patient compliance.
• In May 2022, a drug called Vivjoa (oteseconazolas) received FDA approval for the treatment of both acute and chronic vaginal yeast infections.

Yeast Infection Treatment Market Segmentation by Category:

By Treatment Type:

• Azoles
• Polygene
• Echinocandin
• Others

By Indication:

• Genital Candidiasis
• Invasive Candidiasis
• Oropharyngeal/Esophageal Candidiasis (Thrush)
• Others

By Route of Administration:

• Oral
• Topical
• IV/IM
• Others

By Form:

• Powders
• Creams/Ointments
• Tablets/Capsules
• Others

By Distribution Channel:

• Retail Pharmacies/Drug Stores
• Hospital Pharmacies
• Specialty Stores
• Online Sales
• Others (Hypermarkets/ Conventional Stores)

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle-East and Africa